Barclays Upgrades Sagimet Biosciences to Overweight, Raises Price Target to $18

Benzinga · 1d ago
Barclays analyst Eliana Merle upgrades Sagimet Biosciences (NASDAQ:SGMT) from Equal-Weight to Overweight and raises the price target from $8 to $18.